SavedAdd your journal

Journals / GORM:Gynecology Obstetrics & Reproductive Medicine / 2005 / Cilt: 11 - Sayı: 3

Endometrial changes in breast cancer patients under tamoxifen treatment after levonorgestrel-releasing intrauterine system

Melahat Dönmez KESİM
Yavuz AYDIN
Gül MANDIRACI
Alev ATIŞ
Pages
203–207
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: LNG-IUS system may be useful for preventing unwanted effects of tamoxifen on endometrium and so preventing invasive intervensions causing high costs and patient discomfort and incomplience with the drug.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: To investigate the long term effects of levonorgestrel-releasing intrauterine system on endometrium of breast cancer patients under tamoxifen treatment.
📊
Key Findings & Data:STUDY DESIGN: 142 postmenopausal,breast cancer patient taking tamoxifen treatment were included.
💡
Conclusion & Impact:CONCLUSION: LNG-IUS system may be useful for preventing unwanted effects of tamoxifen on endometrium and so preventing invasive intervensions causing high costs and patient discomfort and incomplience with the drug.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Levonorgestrel · Meme neoplazmları · Endometriyum

Abstract

OBJECTIVE: To investigate the long term effects of levonorgestrel-releasing intrauterine system on endometrium of breast cancer patients under tamoxifen treatment. STUDY DESIGN: 142 postmenopausal,breast cancer patient taking tamoxifen treatment were included. Levonorgestrel releasing intrauterine sistem (LNG-IUS) was fitted to 60 of them which constructed the study group and remaining 82 the control group.All women followed for 24 months. Endometrial biopsies were obtained by histeroscopy,at the begining and at the end of 24th month in both groups. All specimens were histopathologically evaluated. RESULTS: New endometrial polip and/or hyperplasia development were not seen in study group (levonorgestrel IUS fitted patients) after 24 moths of followup of postmenopausal breast cancer patients using tamoxifen. CONCLUSION: LNG-IUS system may be useful for preventing unwanted effects of tamoxifen on endometrium and so preventing invasive intervensions causing high costs and patient discomfort and incomplience with the drug.

🔖

Cite This Article

KESİM, M. D., AYDIN, Y., MANDIRACI, G., ATIŞ, A. (2005). Endometrial changes in breast cancer patients under tamoxifen treatment after levonorgestrel-releasing intrauterine system. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 11 - Sayı: 3, 203–207. https://ajindex.com/articles/227134

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Hammond CB, Soules MR. Endocine Aspects of the Endometrium. In Buchsbaum HJ, Sciarra JJ. Gynecology and Obstetrics. Harper& Row, Publishers, Philadelphia, 1984; 14:1-5
  2. Daniel Y, Inbar M, Bar-Am A, Peyser MR, Lessing JB.The effects of tamoxifen treatment on the endometrium. Fertil Steril 1996; 65:1083-9
  3. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991; 83:1450-9
  4. Baum M, the Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as single adjuvant agent inmanagement of early breast cancer. Br J Cancer 1988; 57:608-11
  5. Early Breast Cancer Trialists' Collaborative Group. Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28.896 women. N Engl J med 1988; 319:1681-92
  6. Gottardis MM, Robinson SP, Satyawaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.Cancer Res 1988; 48:812-5
  7. Speroff L. Uterus. Glass RH, Kase NG, Speroff L (ed). Clinical Gynecologic Endocrinology and Infertility. 5th Ed.Williams & Wilkins, Baltimore 1996; 4:109-612
  8. Neven P. Local levonorgestrel to prevent tamoxifenrelated endometrial lesions. Lancet 2000; 356:1698-99
  9. Bergman L, Beelen MRL, Gallee MPW, Hollema H, Benraadt J, Van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000; 356:881-7
  10. Neven P, Vernaeve H. Guidelines for monitoring patients taking tamoxifen treatment. Drug Safety 2000; 22:1-11. ll.Juneja M, Jose R, Kekre AN, Viswanathan F, Seshadri L. Tamoxifen-induced endometrial changes in postmenopausal women with breast carcinoma. Int J Gynecol Obstet 2002; 76:279-84
  11. Gardner F J E, Konje JC, Abrams KR, et al. Endometrial protection from tamoxifen-stimulated chenges by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000; 356:1711-7. 13.Ballard P, Turnbull L, Richmond I, Tetlow R. Brit J Obstet Gynecol 1998; 105 Suppl 17; Abstr 299
  12. Speroff L. Amenorrhea. Glass RH, Kase NG, Speroff L (ed). Clinical Gynecologic Endocrinology and Infertility. 6th Ed. Williams & Wilkins, Baltimore, 1996; 11:421-86
  13. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351:1451-67
  14. Van Leeuwen FE, Bernaadt J, Coebergh JW, Kiemeney LA; Gimbrere CH, O